DMAC

DiaMedica Therapeutics Inc. - Common Stock (DMAC)

About DiaMedica Therapeutics Inc. - Common Stock (DMAC)

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Details

Daily high

$4.16

Daily low

$3.92

Price at open

$4.02

52 Week High

$6.82

52 Week Low

$2.14

Market cap

177.1M

Dividend yield

0.00%

Volume

78,240

Avg. volume

104,217

P/E ratio

-6.40

DiaMedica Therapeutics Inc. - Common Stock News